SELLAS Life Sciences GroupSLS
Recorded

SELLAS Life Sciences Group Study result

Review the key takeaways and the transcript of this earnings call.

Period 0Duration18 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Greetings, and welcome to the SELLAS Life Sciences Group REGAL Phase III Trial Top-Line Primary Endpoint Results webcast. Participants are in a listen-only mode. As a reminder, this webcast is being recorded. I would now like to turn the floor over to your host, Mr. John Fraunces, with LifeSci Advisors.

John FrauncesManaging Director

Please go ahead. Good morning, and welcome to the SELLAS Life Sciences webcast highlighting the top-line results from the pivotal REGAL Phase III trial.

John FrauncesManaging Director

Joining me on today's call is Dr. Angelos Stergiou, SELLAS' President and Chief Executive Officer. Before we begin, I would like to remind everyone that the company will make forward-looking statements during today's call. These forward-looking statements are subject to inherent risks and uncertainties, and these risks and uncertainties are detailed in the risk factor section of the company's filings with the Securities and Exchange Commission, specifically in the company's annual report on Form 10-K. I'll now turn the call over to Dr. Angelos Stergiou, SELLAS' President and Chief Executive Officer.

Angelos StergiouPresident and CEO

Thank you, John. Good morning, everyone, and thank you for joining us on what is truly a historic day for us. Today marks a defining milestone for SELLAS Life Sciences, a significant moment for cancer immunotherapy, and above all, a day of renewed hope for patients and families facing acute myeloid leukemia. It's the day we've worked toward for 15 long years. We are thrilled to announce positive top-line results from our pivotal Phase III REGAL study evaluating galinpepimut-S, or GPS, our highly innovative WT1-targeted multivalent cancer vaccine immunotherapy in patients with AML who achieved a second or later complete remission or complete remission with incomplete platelet recovery and who are ineligible or unable to undergo allogeneic stem cell transplantation. REGAL met its primary endpoint of overall survival.

Angelos StergiouPresident and CEO

GPS, given on its own as a single agent, delivered a statistically significant and clinically meaningful improvement in survival compared with investigator-selected best available treatment. Let me say that as plainly as I can. In this global randomized Phase III study measured on the endpoint that matters the most, patients who received GPS lived longer and had a significant reduction in risk of death. In oncology, overall survival is the gold standard measurement of whether a medicine truly helps patients live longer. Today, GPS delivered. For these patients and their families, we believe today brings something that has been in very short supply, real hope backed by Phase III survival data. For our cancer vaccine immunotherapy, we believe today is a defining moment for our WT1-targeted approach. Let's look at the numbers.

Angelos StergiouPresident and CEO

REGAL is a global registrational phase III study that randomized 126 patients one-to-one to receive either GPS monotherapy or investigator-select best available treatment, or BAT. Reduction in the risk of death, overall survival, was the pre-specified primary endpoint, evaluated in strict accordance with our pre-specified statistical analysis plan. REGAL achieved its primary endpoint. Median overall survival was 24 months with GPS compared with 14.7 months with BAT. The hazard ratio was 0.59 with a P-value of 0.035. This translates into a 41% reduction in the risk of death compared to active best available treatment. Equally important, GPS achieved a survival benefit while maintaining a favorable safety and tolerability profile, fully consistent with our prior clinical trials and with no new safety signals identified. Treatment-related adverse events were predominantly mild to moderate, grade 1 or 2, most commonly transient local injection site reactions.

Angelos StergiouPresident and CEO

For a fragile patient population already battered by prior lines of intensive chemotherapy, delivering longer life without adding systemic toxicity would be nothing short of transformative. For patients in remission who want to stay in remission and live their lives, a therapy with the potential to extend survival without the burden of toxicity is what has been missing. We will share a comprehensive safety analysis as the full dataset is analyzed and finalized. To truly appreciate the magnitude of today's readout, you have to look closely at the clinical bar GPS just cleared, because two critical aspects of the control arm make the results even more meaningful. First, this was not a study against placebo. Every patient in the control arm received active investigator-selected best available therapy or therapies. Real-world evidence in this high-risk CR2 AML setting has historically shown median survival of approximately eight to 10 months.

Angelos StergiouPresident and CEO

In REGAL, patients on the BAT control arm actually did better than those real-world benchmarks. Let me say plainly, we are genuinely happy about that. Physicians in the control arm were free to choose what they believed was best for each individual patient from the therapies available in the study. Hypomethylating agents such as azacitidine or decitabine, venetoclax, or low-dose cytarabine alone or in any combination. Every patient who entered REGAL on either arm placed their trust in us, and every additional month they gained is a month with people they love. Second, consider the asymmetry of the comparison. In the BAT arm, treating physicians had complete freedom to select any single agent or any multi-drug combination available within the REGAL protocol to give their patients the strongest possible chance, whereas GPS was administered strictly as a monotherapy.

Angelos StergiouPresident and CEO

Beating physician-tailored combination regimens as a single-agent, off-the-shelf cancer vaccine immunotherapy in a setting where no drugs are currently approved as a standard of care underscores both our science and the design of this trial. The implication of today's data could extend far beyond this initial AML population. GPS targets WT1, Wilms tumor one, ranked by the National Cancer Institute as one of the premier cancer antigens in oncology. Crucially, WT1 is overexpressed across approximately 20 distinct tumor types, spanning both hematologic cancers and major solid tumors, including ovarian cancer, malignant pleural mesothelioma, glioblastoma, colorectal, breast, and lung cancers. Over the years, SELLAS and our collaborators have already conducted multiple clinical studies with GPS outside of AML, including in mesothelioma, ovarian cancer, and multiple myeloma, generating promising survival and immune response results. Today's positive phase III REGAL readout, therefore, does more than validate GPS in AML.

Angelos StergiouPresident and CEO

It provides phase III clinical validation of our WT1-targeted immunotherapy and potentially unlocks the broader WT1-expressing oncology landscape. We believe GPS has the makings of a multi-tumor immunotherapy treatment option. With these positive top-line results in hand, we are moving immediately and decisively into our next phase of execution. On the regulatory front, we plan to meet with the U.S. Food and Drug Administration to discuss an accelerated filing strategy and advance preparations for a Biologics License Application, BLA submission, for GPS in the first half of 2027. In parallel, we are advancing manufacturing, regulatory, and launch readiness activities while completing our comprehensive dataset evaluation, including secondary endpoints, pre-specified subgroups, and immunologic correlates, with plans to present the full dataset at a major medical conference and publish in a leading peer-reviewed journal. We will move with urgency, with the scientific rigor and regulatory standards that patients deserve.

Angelos StergiouPresident and CEO

At the same time, let me be crystal clear about our strategic commitment to our shareholders and to the future of this company. We will evaluate every path available to us that is in the best interest of maximizing the value of GPS and SELLAS. Today's phase III readout transforms our strategic position. We do so from a position of strength, with positive phase III survival data in hand, and our leadership team and board are laser-focused on capturing the true value of what we have built. While today rightfully belongs to REGAL and GPS, our broader pipeline continues to build momentum. We are advancing SLS009, our highly selective CDK9 inhibitor, with additional phase II data in relapse or refractory AML slated for presentation at ASH 2026, and initial top-line data from our randomized phase II trial in newly diagnosed AML expected later this year.

Angelos StergiouPresident and CEO

At this point, please allow me to share some deeply personal thoughts and reflections with you today. This year, on October 23rd, SELLAS celebrated its 15th birthday. I still remember day one as vividly as if it were yesterday. As I share these thoughts, I hope you will forgive me if I get a little emotional. It has been a long, long ride, one defined by intense battles and personal sacrifices along the way. They often tell you that in biotechnology, you must be cold and purely rational. They tell you to look only at the data, the balance sheet, and take the safest and most predictable possible path. But I have learned over the years that if you want to develop a safe and effective treatment for cancer, you have to be a dreamer and defiant. The immense size of our dream never faded.

Angelos StergiouPresident and CEO

It has tested us to our limits, but our passion and resilience kept the flame burning bright. Our dream has always been clear: to see patients smile in their greatest time of need because of therapies that we worked tirelessly to bring to life. To rise from a private company fighting to where we are now is a testament to our spirit. Aristotle Onassis once famously said, "The secret in business is knowing something that nobody else knows." Years ago, when I looked at Dr. David Scheinberg's WT1 technology, at what would become GPS, I saw a brilliant, blazing light that others had completely overlooked. When everyone else looked at immunotherapies and cancer vaccines and saw an unviable category, my experience in immunotherapy allowed me to see the individual biological building blocks.

Angelos StergiouPresident and CEO

Memorial Sloan Kettering had engineered a platform that broke immune tolerance, generated long-lasting CD4, CD8 immunity, in part due to the heteroclitic technology. It covered more than 90% of HLA genotypes, targeted an inescapable master oncoprotein, and operated as a scalable off-the-shelf biologic. In-licensing GPS wasn't a gamble on an unproven field. It was the execution of a clear, conviction-driven vision that the second act of cancer vaccines would be defined by brilliant molecular engineering. Over the 15 years, believe me, there were a thousand logical reasons to say I quit. But I endured challenges because quitting meant denying a potentially life-saving therapy for patients in desperate need. On a deeply personal level, I know what these families endure, how they pray, and how vital safe, effective immunotherapies truly are.

Angelos StergiouPresident and CEO

We made it to this point and continue to thrive because of our incredibly loyal shareholders who never lost faith, and an extraordinary team of just 14 people. I want to thank our executive leaders who brought us to this point today. Dragan Cicic, Head of Clinical Development, who worked tirelessly over the years to bring us to this summit. John Burns, our CFO, who skillfully ensured we were equipped and funded to cross the finish line. Andrew Elnatan, leading Regulatory and CMC with outstanding work got us here, and who now carries the torch into our regulatory filings. Stacy Yeung, our General Counsel, who safeguarded our mission and allowed the team to execute seamlessly. Our relentless core team, Nancy, Rohini, Shah, James, Jim, Angela, Sasha, Joel, Ray, and Travis. Finally, thank you to our Board of Directors for their long-term support and belief in our science.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day